Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
AL

NASDAQ · ALVOW

Alvotech

Healthcare · Drug Manufacturers - Specialty & Generic

$0.30

Down-$0.00 (-1.50%)

Updated Sep 13, 2026, 1:16 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
170.79M
P/E ratio
17.23
Dividend yield
0.00%
52-week range
$0.12 – $0.78
Volume
203
Avg. volume
6.07K

Price performance

ALVOW price history

1M range · 11 trading sessions · Daily adjusted prices

ALVOW closed at $0.30 after 11 trading sessions, up 35.86% for the selected period.

Last close
$0.30
Period change
+35.86%
Period low
$0.20
Period high
$0.49
Daily close
View OHLC price history
ALVOW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 8, 2026$0.295$0.2955$0.295$0.2955203
Sep 4, 2026$0.30$0.30$0.30$0.30298
Sep 3, 2026$0.33$0.33$0.30$0.321.92K
Aug 27, 2026$0.3799$0.3799$0.3799$0.3799101
Aug 26, 2026$0.40$0.40$0.40$0.40576
Aug 25, 2026$0.78$0.78$0.49$0.49670
Aug 24, 2026$0.299$0.299$0.299$0.2991.35K
Aug 21, 2026$0.23$0.23$0.2201$0.22011.81K
Aug 20, 2026$0.2017$0.2018$0.198$0.20185.83K
Aug 19, 2026$0.2017$0.2019$0.2017$0.2019389
Aug 17, 2026$0.23$0.23$0.2175$0.21751.22K

Latest ALVOW news

The latest Smart Investors Daily articles mentioning ALVOW.

Stock researchCompany · Overview

ALVOW research

Overview

Company profile and research snapshot.

Company profile

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations

REYKJAVIK, Iceland, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration. Under a partne

Yahoo · Aug 29, 2026

Has Alvotech (NasdaqGM:ALVO) Fallen Below Fair Value After Its Deal?

Alvotech stock has fallen about 50% over the past three years, yet the valuation checks currently lean cheap and the market is reacting positively to fresh licensing deals and regulatory progress. Over the past three years the share price is down about 50%, which means any case for owning Alvotech today rests heavily on a potential recovery from a deep drawdown. A recent licensing agreement with Lotus Pharmaceutical for two biosimilars and ongoing work toward U.S. approvals can support...

Yahoo · Aug 29, 2026

Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical

In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eight Asian markets, with potential consideration of up to approximately US$150 million plus ongoing supply revenues. The deal expands Alvotech’s access to oncology and hematology markets while keeping it in control of development, regulatory approvals, and global product supply. We’ll now examine...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By